AZ’s Upbeat Pipeline Message Tarnished By Federal Probes, Poor Sales
This article was originally published in The Pink Sheet Daily
AstraZeneca highlighted pipeline progress during its quarterly earnings call, but remained on the defensive as analysts questioned two newly disclosed U.S. federal inquiries and the promotion of Marc Dunoyer to CFO, as the Big Pharma struggles with falling sales and profits.
You may also be interested in...
HHS Office of Inspector General’s Mary Riordan advises drug makers to analyze their speaker programs and consulting arrangements for possible kickback activities.
AstraZeneca agreed to pay $200 million upfront and $240 million in predefined milestones for Spirogen to enhance its early oncology pipeline with linked tumor-targeted antibody drug conjugates. The company simultaneously announced a collaboration with ADC Therapeutics to jointly develop ADCs.
Disappointing Phase III results have pushed AstraZeneca to end yet another partnership, leaving Rigel in a tough spot as the biotech considers how to move forward now that its largest partner has jumped ship.